Answers are grounded in this paper and cite their sources.
SummaryThe charts of 132 consecutive patients receiving botulinum toxin type A (BoNT-A; BOTOX®) for headache prevention were reviewed retrospectively. During a follow-up visit, patients reported their overall improvement in headache symptoms. Headache medication utilisation and costs for the 6 months before and during treatment were compared using the Average Wholesale Price. The mean BoNT-A dose used was 101.9 units and 131/132 patients (99%) reported some improvement in headache symptoms. Patients reported an average of 77% improvement in theirBOTOX is a registered trademark of Allergan Inc, Irvine, CA, USAheadache symptoms from baseline. BoNT-A treatment resulted in a 47.2% reduction in the use of headache medications. The average monthly cost of all oral headache medications declined from $242.7 to $89.2, a significant reduction of 63.3% (p < 0.001). A total of 122/132 patients (92.4%) reported no side effects. The cost of BoNT-A treatment appears to be offset to a large degree by the reduction in headache medication usage. Interpretation of these results is limited by the retrospective, uncontrolled and open-label design of the analysis.
No takes yet. Share an insight, caveat, or question.
Peter McAllister (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: